As reported in Figure 4A, expression of the main vitamin C transporters SCL23A2, SLC2A1, and SLC2A3 was significantly reduced in AML patients as compared to HDs (p<0.0001, p=0.0009 and p=0.001, respectively). This evidence concerns the gene SLC2A3 and acute myeloid leukemia.